Resumo
Objetivo: Investigar os impactos da desnutrição proteica e o uso do canabidiol (CBD) sobre a função renal de mulheres grávidas. Avaliar a ação do CBD, a influência da dieta associada a restrição de proteínas para o sistema renal das gestantes e fatores de riscos associados. Revisão bibliográfica: As proteínas são essenciais para os rins, especialmente durante a gestação. A desnutrição proteica em gestantes está relacionada ao aumento do estresse oxidativo e da inflamação, fatores que podem comprometer a função renal materna e prejudicar o desenvolvimento fetal. O CBD, um composto extraído da planta Cannabis sativa, com propriedades anti-inflamatórias e antioxidantes, tem sido apontado como um potencial terapêutico para diminuir esses danos. Esse fitoterápico exerce suas funções ao modular o sistema endocanabinóide (SEC), reduzindo citocinas pró-inflamatórias e inibindo vias inflamatórias. E sua ação antioxidante ocorre pela neutralização de radicais livres, protegendo as células contra danos. Considerações finais: Embora, estudos apresentarem propriedades fitoterápicas do CBD, a eficácia e segurança do seu uso durante a gravidez ainda não são totalmente compreendidas. Pesquisas experimentais e clínicas são essenciais para esclarecer seus efeitos, e viabilizar intervenções terapêuticas mais eficazes.
Referências
ALVES CH, et al. Maternal protein restriction reduces ACE2 expression in the placenta and fetal kidneys: implications for fetal programming of hypertension. Placenta, 2020; 91:e55–e63.
ARAÚJO M, et al. The cannabinoids mechanism of action: an overview. BrJP, 2023; 6:e109–e113.
AZOUZI S, et al. Antioxidant and membrane binding properties of serotonin protect lipids from oxidation. Biophysical Journal, 2017; 112(9):1863–1873.
BASTO JP, et al. La relación entre el sistema endocannabinoide y la adicción a la comida: una revisión exploratoria. Revista Española de Nutrición Humana y Dietética, 2021; 25(2):e1–e34.
BELLIZZI V, CUPISTI A. Dietary approach to kidney disease. Clinical Journal of the American Society of Nephrology, 2016; 11(12):2065–2075.
BEAS BC, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 2015; 12(4):699–730.
BRENNER BM, RECTOR FC. The Kidney. 9th ed. Philadelphia: Elsevier Saunders; 2012.
BUSQUETS-GARCIA A, BAINS J, MARSICANO G. CB1 receptor signaling in the brain: extracting specificity from ubiquity. Neuropsychopharmacology, 2018; 43(1):4–20.
CAIRASCO NG, et al. Cannabidiol attenuates cisplatin-induced nephrotoxicity in rats. European Journal of Pharmacology, 2015; 749:1–9.
CAO Y, et al. Oxidative stress in maternal and offspring kidney disease and programming. Antioxidants, 2020; 9(9):825.
FORGIE AJ, et al. O impacto da desnutrição materna e precoce na saúde: uma perspectiva dieta-micróbio. BMC Medicine, 2020; 18:1–15.
FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS (FAO). The State of Food Security and Nutrition in the World 2023. Rome: FAO; 2023. Disponível em:
https://www.fao.org/documents/card/en/c/CC3017EN. Acesso em: 06 maio 2025.
GARNEATA L, et al. Low-protein diet supplemented with ketoacids and its effect on diabetic nephropathy. Nephrology Dialysis Transplantation, 2018; 33(1):617.
GAUVEIA MA. Nutrição e suplementação no período gestacional. Dissertação (Mestrado em Ciências Farmacêuticas). Universidade de Lisboa; 2022. 47 p.
GRANT KS, et al. Cannabis use during pregnancy: pharmacokinetics and effects on child development. Pharmacology & Therapeutics, 2018; 182:133–151.
GUYTON AC, HALL JE. Textbook of Medical Physiology. 14th ed. Philadelphia: Elsevier; 2021.
IBEAS BIH C, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 2015; 12(4):699–730.
IEZZI D, et al. In utero exposure to cannabidiol disrupts select early-life behaviors in a sex-specific manner. Translational Psychiatry, 2022; 12(1):501.
JOHNSON RJ, et al. What happens to your body when you don't eat enough protein every day. Verywell Health, 2025. Disponível em: https://www.verywellhealth.com/protein-deficiency-symptoms-8756264. Acesso em: 06 maio 2025.
KAMEL RM, et al. Association between maternal serum albumin and preeclampsia severity: a prospective study. Pregnancy Hypertension, 2022; 30:72–78.
KIM JH, et al. Anti-inflammatory effects of cannabidiol isolated from a novel hemp cultivar (Cannabis sativa L.). Molecules, 2023; 28(18):6439.
KOLTZKO B, et al. Nutrition during pregnancy, lactation and early childhood and its implications for maternal and long-term child health: the Early Nutrition Project recommendations. Annals of Nutrition and Metabolism, 2019; 74(2):93–106.
KSIAZEK SH, et al. Renin-angiotensin-aldosterone system: from history to practice of a secular topic. International Journal of Molecular Sciences, 2024; 25(7):4035.
LIU Y, et al. Dietary protein intake and hypertension risk: a meta-analysis. Nutrition Reviews, 2018; 76(9):601–612.
LU HC, MACKIE K. An introduction to the endogenous cannabinoid system. Biological Psychiatry, 2016; 79(7):516–525.
LU HC, MACKIE K. Review of the endocannabinoid system. Biological Psychiatry, 2021; 90(2):84–95.
MACCARRONE M, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences, 2015; 36:277–296.
MAIA J, et al. The fundamental role of the endocannabinoid system in endometrium and placenta. Human Reproduction Update, 2020; 26(5):586–602.
MARINHO AM, SILVA NR. Anti-inflammatory effects of cannabinoids. BrJP, 2023; 6:31–37.
MAVRIDIS A, et al. Pregnancy and renal disease: a review. Journal of Nephrology, 2021; 31(5):781–793.
MCPARTLAND JM, et al. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? British Journal of Pharmacology, 2015; 172(3):737–753.
OGAWA N, et al. Functional and structural divergence in human TRPV1 channel subunits by oxidative cysteine modification. Journal of Biological Chemistry, 2016; 291(8):4197–4210.
PARK F, et al. Cannabinoids and the kidney: effects in health and disease. American Journal of Physiology – Renal Physiology, 2017; 313(5):1124–1132.
PEREIRA AF. Participação do sistema endocanabinoide na neuromodulação da neuropatia sensitiva periférica induzida por oxaliplatina em camundongos. Tese (Doutorado em Farmacologia). Universidade Federal do Ceará; 2020.
PICCOLI GB, et al. Risk of adverse pregnancy outcomes in women with chronic kidney disease. Journal of Nephrology, 2020; 33(6):1147–1157.
ROSS MH, PAWLINA W. Histology: A Text and Atlas. 8th ed. Philadelphia: Wolters Kluwer; 2020.
STAROWICZ K, FINN DP. Cannabinoids and pain: sites and mechanisms of action. In: Advances in Pharmacology. Elsevier; 2017. p. 437–475.
STENVINKEL P, ZOCCALI C. Kidney disease in disadvantaged populations. Nephrology Dialysis Transplantation, 2017; 32(1):21–25.
SWENSON KS, et al. Prenatal cannabidiol exposure alters pain sensitivity and cortical excitability. Molecular Psychiatry, 2023; 28:3397–3413.
TABACH R, et al. Sistema de farmacovigilância em plantas medicinais. Boletim Planfavi, 2019; 52:1–4.
TABRIZI MA, et al. Medicinal chemistry, pharmacology and clinical implications of TRPV1 receptor antagonists. Medicinal Research Reviews, 2017; 37(4):936–963.
TORTORA GJ. Princípios de anatomia e fisiologia. 14ª ed. Rio de Janeiro: Guanabara Koogan; 2019.
TRIEBEL H, CASTROP H. The renin angiotensin aldosterone system. Pflügers Archiv, 2024; 476(5):705–713.
VALLÉE A, et al. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ. Acta Biochimica et Biophysica Sinica, 2017; 49(10):853–866.
VITOLA LA, et al. Prospects in the use of Cannabis sativa extracts in nanoemulsions. Pharmaceuticals, 2024; 17(2):116.
VOLKOW ND, et al. Self-reported medical and nonmedical cannabis use among pregnant women in the United States. JAMA, 2019; 322:167.
ZHOU X, et al. Inflammation and oxidative stress in chronic kidney disease. International Journal of Molecular Sciences, 2017; 18(5):969.
ZON S, et al. Avaliação do papel do sistema canabidiol em um modelo de lesão renal por isquemia/reperfusão. Revista Brasileira de Terapia Intensiva, 2015; 27(4):383–389.
